Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Proc (Bayl Univ Med Cent) ; 26(3): 262-4, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23814384

ABSTRACT

Glossopharyngeal neuralgia (GPN) is a rare disorder of the ninth cranial nerve characterized by severe paroxysmal pain affecting the ear, tongue, and throat. GPN can be associated with life-threatening issues such as cardiac arrhythmias, syncope, or malnutrition and weight loss from odynophagia. Though traditional treatment for GPN involves medical management at first and surgery for refractory cases, these therapies are often poorly tolerated in the elderly population. We describe the case of a 99-year-old woman, the oldest reported patient with GPN treated successfully with Gamma Knife radiosurgery. We conclude that Gamma Knife radiosurgery for GPN can be both effective and very well tolerated in the elderly and deserves further study and careful consideration as a treatment option in this population.

2.
Liver Transpl ; 18(8): 949-54, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22467602

ABSTRACT

Hepatocellular carcinoma (HCC) is potentially curable with hepatic resection or transplantation. Few patients are eligible for resection, and many face a long wait for donor organ availability for liver transplantation. Here we report the safety and efficacy of stereotactic body radiation therapy (SBRT), the explant pathology findings and survival of patients treated with SBRT as a bridge to transplantation for HCC. From April 2005 to August 2010, 10 patients with 11 HCCs were treated with SBRT as a bridge to transplantation. All patients were evaluated by a liver transplant surgeon before radiosurgery. SBRT was delivered with the CyberKnife robotic radiosurgery system. After SBRT, all patients underwent orthotopic liver transplantation. The tumor response was determined by explant pathology. The median follow-up was 62 months from the time of SBRT. The mean time on the liver transplant wait list was 163 days. The median tumor size was 3.4 cm (range = 2.5-5.5 cm). The median SBRT dose was 51 Gy (range = 33-54 Gy) in 3 fractions. The median time from SBRT to liver transplantation was 113 days (range = 8-794 days). At 5 years, the overall survival rate and the disease-free survival rate were both 100%. Overall, 4 of the 10 patients (40%) experienced acute toxicity. Most toxicities were grade 1, and they included nausea, fatigue, and abdominal discomfort. One patient had grade 2 nausea/vomiting. Explant pathology revealed no viable tumor in 3 of the 11 tumors for a complete response rate of 27%. The remaining 8 tumors decreased or remained stable in size. In conclusion, with a median follow-up over 5 years, we have found that SBRT as a bridge to liver transplantation for HCC is feasible and well tolerated. SBRT for HCC may enable patients to remain on the list for frequently curative transplantation during the wait for organ availability.


Subject(s)
Carcinoma, Hepatocellular/radiotherapy , Radiosurgery/methods , Adult , Aged , Carcinoma, Hepatocellular/therapy , Disease-Free Survival , Dose-Response Relationship, Radiation , Female , Humans , Liver Neoplasms/therapy , Liver Transplantation/methods , Magnetic Resonance Imaging/methods , Male , Middle Aged , Time Factors , Tomography, X-Ray Computed/methods , Treatment Outcome
3.
Proc (Bayl Univ Med Cent) ; 21(3): 266-80, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18628926

ABSTRACT

Hepatocellular carcinoma (HCC) is a common cancer that typically occurs in the setting of cirrhosis and chronic hepatitis virus infections. Hepatitis B and C account for approximately 80% of cases worldwide. HCC is currently the fifth most common malignancy in men and the eighth in women worldwide; its incidence is increasing dramatically in many parts of the world. Recognition of those at risk and early diagnosis by surveillance with imaging, with or without serologic testing, are extremely important. Many highly effective and even curative therapies are now available and include resection, liver transplantation, and local ablation. Appropriate application of these interventions offers hope of prolonged survival to many patients with this otherwise lethal complication of liver disease.

4.
Clin Genitourin Cancer ; 5(1): 85-8, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16859585

ABSTRACT

The objective of this study was to evaluate the acute tolerance to definitive external-beam radiation therapy (RT; EBRT) in patients with prostate adenocarcinoma and HIV and to review the published literature for this population. Three patients with prostate adenocarcinoma and HIV were treated with definitive RT. Medical records were reviewed for prostate cancer and HIV characteristics, RT details, and acute toxicity. A review of the published literature was performed for epidemiology, management, and outcome of these patients. All 3 patients had excellent acute tolerance to definitive EBRT and, with short follow-up, all had decreasing prostate-specific antigen levels. The published literature regarding patients with prostate adenocarcinoma and HIV is scarce but suggests that men with HIV might be at higher risk of developing prostate cancer. External-beam radiation therapy, brachytherapy, and surgery have all been used in the management of these patients. All 3 patients with prostate adenocarcinoma and HIV had an excellent acute tolerance to EBRT. Prostate cancer is expected to become an increasingly important health problem for men infected with HIV as their life expectancy lengthens.


Subject(s)
Adenocarcinoma/complications , Adenocarcinoma/radiotherapy , HIV Infections/complications , Prostatic Neoplasms/complications , Prostatic Neoplasms/radiotherapy , Humans , Male , Middle Aged , Treatment Outcome
5.
Int J Radiat Oncol Biol Phys ; 65(5): 1411-5, 2006 Aug 01.
Article in English | MEDLINE | ID: mdl-16750309

ABSTRACT

PURPOSE: Topoisomerase II alpha (Topo II alpha) plays a role in DNA replication and is the molecular target for anthracyline-based chemotherapy. The purpose of this study was to evaluate the relationship between Topo II alpha expression and survival in patients with invasive breast cancer. METHODS AND MATERIALS: Formalin-fixed, paraffin-embedded tumor specimens from 24 women with invasive breast cancer were stained for Topo II alpha expression. All women underwent mastectomy. Radiotherapy was given at the University of Utah Department of Radiation Oncology. Of the patients, 23 (96%) received chemotherapy. The level of Topo II alpha expression within tumor cells was compared with clinical factors and overall survival. RESULTS: The median percentage of tumor cells expressing Topo II alpha was 70%. Increased Topo II alpha tumor expression significantly correlated with diminished disease-free survival. Five-year disease-free survival was 100% for patients with <70% of breast cancer cells expressing Topo II alpha compared with 42% for patients with > or =70% Topo II alpha expression (p = 0.008). The level of Topo II alpha expression within tumor cells correlated with T stage (p = 0.008) but not with other pathologic factors. CONCLUSIONS: Increased Topo II alpha expression significantly correlated with diminished disease-free survival in patients with invasive breast cancer. These findings may indicate a role for Topo II alpha expression as a prognostic factor in breast cancer.


Subject(s)
Antigens, Neoplasm/metabolism , Biomarkers, Tumor/metabolism , Breast Neoplasms/enzymology , Breast Neoplasms/mortality , DNA Topoisomerases, Type II/metabolism , DNA-Binding Proteins/metabolism , Adult , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/enzymology , Carcinoma, Ductal, Breast/mortality , Carcinoma, Ductal, Breast/pathology , Chemotherapy, Adjuvant , Disease-Free Survival , Female , Humans , Mastectomy , Radiotherapy, Adjuvant
6.
Int J Radiat Oncol Biol Phys ; 63(4): 1060-6, 2005 Nov 15.
Article in English | MEDLINE | ID: mdl-15978737

ABSTRACT

PURPOSE: To evaluate a single institution's experience with intraoperative radiation therapy (IORT) in combination with attempted surgical resection for pancreatic and periampullary adenocarcinoma. METHODS AND MATERIALS: From May 1986 until June 2001, 77 patients at LDS Hospital underwent attempted surgical resection and IORT for pancreatic or periampullary adenocarcinoma. A potentially curative resection was defined as surgery with negative or microscopic positive margins. No patients had metastatic disease at the time of surgery and IORT. Forty-four patients with tumors located in the pancreas and 9 patients with periampullary tumors underwent potentially curative surgical resection and IORT. Twenty-four patients had pancreatic tumors deemed unresectable and underwent surgical bypass and IORT. Actuarial survival was calculated from the date of IORT until last follow-up or death by use of the Kaplan-Meier method. RESULTS: Patients undergoing a potentially curative resection and IORT for periampullary adenocarcinoma had a median survival of 167 months and a 56% 5-year actuarial survival, compared with a median survival of 16 months and a 19% 5-year actuarial survival for patients undergoing the same treatment for pancreatic adenocarcinoma (p = 0.03). Patients with unresectable disease who underwent bypass and IORT had a median survival of 11 months and a 0% 3-year survival, significantly worse than patients able to undergo surgical resection and IORT (p = 0.0002). The operative mortality for all patients undergoing potentially curative resection and IORT was 3.7%. CONCLUSIONS: Intraoperative radiation therapy is well tolerated and does not increase the morbidity or mortality of potentially curative surgical resection for pancreatic or periampullary adenocarcinoma. Patients with periampullary adenocarcinoma have a better prognosis than those with pancreatic adenocarcinoma, and patients with unresectable pancreatic disease fared worse.


Subject(s)
Adenocarcinoma/mortality , Ampulla of Vater , Common Bile Duct Neoplasms/mortality , Pancreatic Neoplasms/mortality , Adenocarcinoma/drug therapy , Adenocarcinoma/radiotherapy , Adenocarcinoma/surgery , Adult , Aged , Aged, 80 and over , Chemotherapy, Adjuvant , Combined Modality Therapy , Common Bile Duct Neoplasms/drug therapy , Common Bile Duct Neoplasms/radiotherapy , Common Bile Duct Neoplasms/surgery , Female , Fluorouracil/administration & dosage , Humans , Intraoperative Period , Male , Middle Aged , Neoplasm, Residual , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/radiotherapy , Pancreatic Neoplasms/surgery , Pancreaticoduodenectomy , Statistics, Nonparametric , Survival Analysis
7.
Int J Radiat Oncol Biol Phys ; 58(4): 1034-40, 2004 Mar 15.
Article in English | MEDLINE | ID: mdl-15001242

ABSTRACT

PURPOSE: To evaluate the relationship between cyclooxygenase-2 (COX-2) expression and pathologic features and outcome in invasive breast cancer. METHODS AND MATERIALS: Formalin-fixed, paraffin-embedded tumor specimens from 23 women with invasive breast cancer were stained for COX-2 expression. All women underwent mastectomy and locoregional radiotherapy. The distribution (percentage of positive staining cells) and intensity of COX-2 expression within the tumor cells were compared with clinical factors, including stage, grade, lymph node involvement, and outcome. RESULTS: For invasive breast cancer, the distribution and intensity of COX-2 tumor expression correlated significantly with diminished overall survival. The 5-year overall survival rate was 100% for patients with <75% of breast cancer cells expressing COX-2 compared with 49% for patients with > or =75% (p = 0.044). The 5-year overall survival rate was 100% for patients with COX-2 intensity <80 compared with 60% for patients with COX-2 intensity > or =80 (p = 0.018). The percentage and intensity of COX-2 expression also correlated significantly with disease-free survival. The percentage of cells expressing COX-2 was significantly greater in women <40 years old than in women > or =40 years old (81% vs. 59%, respectively, p = 0.04). CONCLUSION: Both the distribution and the intensity of COX-2 expression correlated significantly with disease-free and overall survival in patients with invasive breast cancer. Younger patients with invasive breast cancer may have a greater percentage of COX-2 expression in their tumors.


Subject(s)
Breast Neoplasms/enzymology , Breast Neoplasms/mortality , Isoenzymes/analysis , Neoplasm Proteins/analysis , Prostaglandin-Endoperoxide Synthases/analysis , Adult , Breast Neoplasms/therapy , Combined Modality Therapy , Cyclooxygenase 2 , Female , Humans , Mastectomy , Membrane Proteins , Prognosis , Statistics as Topic , Survival Rate
SELECTION OF CITATIONS
SEARCH DETAIL
...